MECP2 Gene Rett Syndrome clinical trials
10 active Rett Syndrome trials that test for MECP2 Gene in their eligibility criteria. Describe your situation to see which ones look like a fit.
- A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
- Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
- To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
- Auditory EEG and Behavioral Assessments in Individuals With Rett Syndrome
- Validating Innovative Biosensors for Rett Autonomic Symptom Tracking
- Neurophysiologic Biomarkers in Rett Syndrome
- Rett Syndrome Registry
- The Rett Syndrome Global Registry
- A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
- A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.